The objective of this study was to investigate whether percentage of mature oocytes retrieved from ovaries stimulated with long agonist or multi-dose antagonist protocols affect the implantation, clinical pregnancy and live birth of ICSI (Intracytoplasmic sperm injection) cycles. The 654 cycles of agonist (long lupron) and 610 cycles of multi-dose flexible antagonist (antagon) were analyzed after stratification according to the percentage of the mature oocytes retrieved. The clinical pregnancy of the groups with less than 30 % mature oocytes retrieved, both antagonist and agonist protocol was statistically lower (at least p< 0.05) compared to the groups with more than 30% mature oocytes retrieved. In the agonist protocol, the implantation and live births for this group were significantly (p<0.009) lower than in the group with ≥70% mature oocytes retrieved. The live births in groups with more mature oocytes retrieved (30-69% and ≥70 %) of the antagonist protocol were lower (22.2% vs. 35.9% and 23.9% vs. 41.5%, p<0.0001, respectively) compare to the agonist protocol.
Introduction
Since the early 1980's a variety of controlled ovarian hyperstimulation (COH) protocols with the use of gonadotrophin-releasing hormone (GnRH) analogues (agonists or antagonists) in conjunction with gonadotropins/menotropins have been developed [1] [2] [3] [4] .
The addition of GnRH analogues significantly reduced the incidence of premature LH surges and cycle cancellations, leading to a higher number of oocytes retrieved, with an improved outcome of infertility treatments [5] [6] [7] [8] . Despite a significant number of studies [3, 12, 13, 31, 34, 38, 40, 42, 48, 52] comparing both long GnRH agonist and GnRH antagonist protocols, the superiority of one over another is still widely debated in the literature.
The mechanism of action of these two analogues (agonist and antagonist) is different. In the long agonist protocol, antral follicles are recruited by exogenous gonadotropin after early depletion of endogenous hormones. In the antagonist protocol the endogenous hormones recruit follicles. GnRH antagonist controls gonadotropin secretion by its immediate suppression in the pituitary. The use of the antagonist is associated with a shorter time of stimulation, reduced gonadotropin consumption and a reduced ovarian hyperstimulation incidence (OHSS) as well as a different pattern of steroid hormones concentration in the blood and follicular fluid [9] , when compared to the agonist protocol [10] [11] [12] [13] [14] . The differences in the endocrine environment for maturing oocytes may alter the ovarian folliculogenesis and influence the oocyte quality [15] [16] [17] and subsequently embryo development [18] . It has been demonstrated that embryos derived from the women stimulated with the flexible GnRH antagonist protocol underwent faster with the earliest cleavage than embryos derived from women stimulated with a long GnRH agonist protocol [19] .
Previously, a positive correlation between the follicle size, oocyte maturity and pregnancy rate of women undergoing IVF, has been reported [20] [21] [22] [23] [24] [25] .
Others [26] [27] [28] demonstrated that larger leading follicles yield better pregnancy rates, but not necessarily a higher percentage of mature oocytes or availability of embryos for transfer [25] . Teissier et al. [17] showed a discrepancy between the size and maturity status of the oocytes collected from the patients stimulated with the agonist protocol. They found mature oocytes were present in smaller follicles, and immature in larger follicles. Nogueira et al showed a significantly higher percentage of immature oocytes were retrieved from large follicles in antagonist cycles when compared to the agonist protocol [27] . They found also a greater heterogeneity in maturity of oocytes retrieved from patients stimulated with antagonist. Therefore, taking into consideration the information available in the literature, we undertook the present study to determine whether a low, medium or high percentage of mature oocytes retrieved may influence the clinical outcome of the two commonly used ovarian stimulation protocols (flexible multi-dose antagonist and long agonist) in IVF patients.
Materials and Methods
The study was approved by the Institutional Review Board of the Abington Memorial Hospital, PA. 
Results
The distribution of diagnoses (endometriosis, idiopathic, male factor, ovulatory dysfunction, tubal, polycystic ovary syndrome, diminished ovarian reserve or advanced maternal age) in our antagonist and agonist protocol study groups is presented in Table I . The majority of patients in both treatment protocols were diagnosed as male factor (approx. 45%) and diminished ovarian reserve (approx. 25%).
The use of the antagonist or agonist in the ovarian stimulation protocols did not have any effect (Table II) .
However, in the antagonist protocol treated group of ≥70 % matured oocytes retrieved, there was a tendency (p<0.053) in enrolling more older patients.
Consequently, the difference in the age (p<0.001) between the two treatment protocols of the groups with ≥70 % mature oocytes was established. The endometrium was significantly thinner in the antagonist protocol groups (p<0.004, p<0.001and p<0.002, respectively) compared to the agonist. The estradiol level at time of HCG injection was significantly (p<0.001) lower for the antagonist of second (31-69%) and third (≥70%) group compared to corresponding agonist groups (Table II) .
There were no differences in the number of eggs retrieved between the antagonist groups. However, the first agonist protocol group (≤30% mature oocytes)
had the lowest number of retrieved oocytes (p<0.04) when compared to other groups using this protocol (Table III) . The number of mature and fertilized (2PNs) oocytes gradually increased (p<0.001) as more mature oocytes were retrieved in each of both protocol groups (Table III) . There were no differences in the number of transferred embryos between each protocol group , as well as between the treatment protocols. There were no differences in the fertilization rate between the antagonist and agonist protocol groups (Table III ). The differences between the treatment protocols (antagonist vs. agonist) were determined among the groups 31-69%
and ≥70 % mature oocytes in the number of retrieved Additionally, the fertilization rate of the agonist group with ≥70% of mature oocytes was significantly higher (p<0.03) compared to the corresponding antagonist protocol group (Table III) . The overall number of retrieved, mature and, fertilized oocytes was significantly higher (p<0.05) in the agonist protocol when compared to the antagonist protocol (data not shown).
There were no differences in implantation, and live births between the three studied antagonist protocol groups ( 
Discussion
In our study, the groups with low ovarian response (less than 30 % of mature oocytes retrieved) of the antagonist (antagon) and the agonist (long lupron) were comparable in terms of characteristics assessed (endocrinological and embryological) and the clinical outcome (implantation, clinical pregnancy and live births). Similarly, Al-Inany et al. [29] showed no differences in clinical pregnancy rates between the GnRH antagonist and the GnRH agonist treatment in patients with low ovarian responses or PCO patients [30] . However, in our study, the groups with low Note: NS = not statistically significant. The column P value shows the level of statistical differences between the three studied groups. Values with different letters are different. The asterisks stand for the difference between the antagonist and agonist protocols (p<0.0009 for the groups 30-69% and p< 0.0001 for the groups with ≥70% matured oocytes). [29] that is contrary to their previous reports [1, 33] , has demonstrated no evidence of statistically significant differences in the rates of live births or ongoing pregnancies when comparing GnRH agonist long protocols with antagonist protocols. A meta-analysis by Xiao et al. [34] showed that ongoing pregnancy and live births were similar in the GnRH antagonist when 10.14302/issn.2576-2818.jfb-17-1435 Vol-1 Issue 1 Pg. no.-41 ratio and was explained by the endometrial impact of a lower LH level [44] . Higher pregnancy rates in the agonist cycles may be a result of larger number of oocytes and embryos for selection for transfer [45] .
Demonstrated differences in the number of M II and 2PNs between the studied groups of both protocols in our study were more likely to be a result of enforced stratification of the data. Therefore, in each group of both protocols, the number of mature and fertilized oocytes were progressively increasing with parallel increase in estradiol level in the blood produced by of the follicular cohort [27] so that lower number oocytes were retrieved. Moreover, the differences between these two protocols might be due to a different mechanism of GnRH actions. In the agonist (long protocol) after a variable period of endogenous gonadotrophin depletion, small antral follicles are recruited by the exogenous gonadotropins. In contrast, in the antagonist cycle, the recruited follicles have already been exposed for a few days to endogenous inter-cycle FSH rise [1, 53, 54] . Administration of the GnRH antagonist at the end of the stimulation period could have had an effect on the cell cycle of granulosa cells [55] . In vitro studies showed that GnRH-antagonist restrains cell growth by decreasing the synthesis and the stimulatory effects of IGFs on follicle growth [56] . GnRH may act as an autocrine factor by regulating mitogenactivated protein kinase in human granulosa luteal cells [57, 58] and affect the follicles environment. Young et al. In conclusion, clinical outcomes appear to be influenced by the percentage of mature oocytes retrieved especially when the percentage of retrieved mature oocytes is low. It is essential to establish ovarian sensitivity to gonadotropins before any type of individualized approach of controlled ovarian stimulation protocol will be applied. Clin. Endocrinol, vol. 44, pp. 191-198, 1996 . [24] C. Bergh, H. Broden, K. Lundin, L. Hamberger.
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